SCHEMBL7908783

SCHEMBL7908783

C[C@H](NC(=O)C1(c2ccccc2)CCN(C(=O)c2ccc(N3CCOCC3)cc2)CC1)c1ccccc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.55
ALDH1A1 P00352 3/20 0.50
MEN1 O00255 1/20 0.48
KMT2A Q03164 1/20 0.48
TP53 P04637 2/20 0.48
HTT P42858 1/20 0.48
ATM Q13315 1/20 0.45
AURKA O14965 2/20 0.45
HPGD P15428 2/20 0.44
CYP3A4 P08684 2/20 0.44
KCNQ3 O43525 1/20 0.44
KCNQ2 O43526 1/20 0.44
CYP1A2 P05177 1/20 0.44
CYP19A1 P11511 1/20 0.44
CYP2C9 P11712 1/20 0.44
CA12 O43570 1/20 0.44
CA1 P00915 1/20 0.44
CA2 P00918 1/20 0.44
CA7 P43166 1/20 0.44
CA9 Q16790 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13092193 0.92 TSHR (0.47) TSHRALDH1A1MEN1KMT2AATM
SCHEMBL7901820 0.91 TSHR (0.46) TSHRALDH1A1MEN1KMT2AATM
SCHEMBL13092179 0.90 PIN1 (0.47) TSHRALDH1A1MEN1KMT2ATP53
SCHEMBL7907440 0.89 TSHR (0.44) TSHRALDH1A1TP53HTTATM
SCHEMBL7909073 0.87 ALDH1A1 (0.55) TSHRALDH1A1KMT2ATP53HTT
SCHEMBL13092183 0.86 CYP2D6 (0.48) TSHRALDH1A1MEN1KMT2AATM
SCHEMBL7909164 0.86 POLB (0.50) TSHRALDH1A1MEN1KMT2AATM
SCHEMBL13092209 0.84 USP2 (0.45) TSHRALDH1A1TP53HTTATM
SCHEMBL13092229 0.83 CA12 (0.48) TSHRALDH1A1MEN1KMT2AATM
SCHEMBL13092248 0.83 MEN1 (0.45) TSHRALDH1A1MEN1KMT2AATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8324250-B2 Piperidine derivatives as NK3 receptor antagonists HOFFMANN-LA ROCHE INC. (US) 2012-12-04 US disclosed
US-8324250-B2 Piperidine derivatives as NK3 receptor antagonists HOFFMANN-LA ROCHE INC. (US) 2012-12-04 US disclosed
US-20100256126-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS HOFFMANN-LA ROCHE, INC. 2010-10-07 US disclosed
US-20100256126-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS HOFFMANN-LA ROCHE, INC. 2010-10-07 US disclosed
WO-2010106081-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2010-09-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256126-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS HTR3A, OPRL1, OPRK1 TSHR 895/4885ALDH1A1 480/4885MEN1 4869/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.